KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Cash & Equivalents (2016 - 2025)

Resmed (RMD) has disclosed Cash & Equivalents for 17 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 171.5% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, up 171.5%, and an annual FY2025 reading of $1.2 billion, up 407.4% over the prior year.
  • Cash & Equivalents was $1.4 billion for Q4 2025 at Resmed, up from $1.4 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.4 billion in Q4 2025 and bottomed at $194.5 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $458.8 million, with a median of $245.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 36.25% in 2021, then skyrocketed 407.4% in 2025.
  • Year by year, Cash & Equivalents stood at $194.5 million in 2021, then skyrocketed by 30.2% to $253.2 million in 2022, then decreased by 16.96% to $210.2 million in 2023, then surged by 148.25% to $521.9 million in 2024, then skyrocketed by 171.5% to $1.4 billion in 2025.
  • Business Quant data shows Cash & Equivalents for RMD at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.2 billion in Q2 2025.